News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
382,128 Results
Type
Article (25981)
Company Profile (59)
Press Release (356088)
Multimedia
Podcasts (25)
Webinars (7)
Section
Business (104333)
Career Advice (453)
Deals (16887)
Drug Delivery (51)
Drug Development (47679)
Employer Resources (47)
FDA (12273)
Job Trends (8445)
News (186103)
Policy (19433)
Tag
Academia (1753)
Accelerated approval (3)
Adcomms (8)
Allergies (73)
Alliances (26772)
ALS (57)
Alzheimer's disease (812)
Antibody-drug conjugate (ADC) (52)
Approvals (12336)
Artificial intelligence (170)
Autoimmune disease (11)
Automation (4)
Bankruptcy (144)
Best Places to Work (6897)
BIOSECURE Act (5)
Biosimilars (36)
Biotechnology (39)
Bladder cancer (59)
Brain cancer (17)
Breast cancer (193)
Cancer (1438)
Cardiovascular disease (121)
Career advice (410)
Career pathing (13)
CAR-T (71)
Cell therapy (203)
Cervical cancer (13)
Clinical research (40589)
Collaboration (443)
Compensation (130)
Complete response letters (9)
COVID-19 (1495)
CRISPR (12)
C-suite (141)
Cystic fibrosis (42)
Data (1541)
Decentralized trials (2)
Denatured (17)
Depression (30)
Diabetes (177)
Diagnostics (3524)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (13)
Drug discovery (52)
Drug pricing (54)
Drug shortages (21)
Duchenne muscular dystrophy (56)
Earnings (36962)
Editorial (20)
Employer branding (6)
Employer resources (44)
Events (51848)
Executive appointments (451)
FDA (13274)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (3)
Funding (403)
Gene editing (37)
Generative AI (10)
Gene therapy (127)
GLP-1 (403)
Government (3036)
Grass and pollen (3)
Guidances (51)
Healthcare (12192)
Huntington's disease (10)
IgA nephropathy (16)
Immunology and inflammation (41)
Indications (19)
Infectious disease (1565)
Inflammatory bowel disease (80)
Inflation Reduction Act (4)
Influenza (26)
Intellectual property (50)
Interviews (40)
IPO (7040)
IRA (19)
Job creations (1839)
Job search strategy (381)
Kidney cancer (7)
Labor market (10)
Layoffs (171)
Leadership (4)
Legal (3632)
Liver cancer (57)
Lung cancer (232)
Lymphoma (100)
Machine learning (3)
Management (17)
Manufacturing (104)
MASH (49)
Medical device (12910)
Medtech (12913)
Mergers & acquisitions (10138)
Metabolic disorders (439)
Multiple sclerosis (54)
NASH (11)
Neurodegenerative disease (49)
Neuropsychiatric disorders (9)
Neuroscience (1146)
NextGen: Class of 2025 (3934)
Non-profit (2824)
Now hiring (16)
Obesity (220)
Opinion (71)
Ovarian cancer (52)
Pain (65)
Pancreatic cancer (55)
Parkinson's disease (88)
Partnered (11)
Patents (114)
Patient recruitment (82)
Peanut (37)
People (34743)
Pharmaceutical (17)
Pharmacy benefit managers (11)
Phase I (11629)
Phase II (17569)
Phase III (14437)
Pipeline (698)
Policy (60)
Postmarket research (1671)
Preclinical (3633)
Press Release (18)
Prostate cancer (77)
Psychedelics (17)
Radiopharmaceuticals (160)
Rare diseases (183)
Real estate (2847)
Recruiting (16)
Regulatory (14226)
Reports (16)
Research institute (1609)
Resumes & cover letters (49)
Rett syndrome (2)
RNA editing (2)
RSV (20)
Schizophrenia (51)
Series A (66)
Series B (49)
Service/supplier (3)
Sickle cell disease (21)
Special edition (3)
Spinal muscular atrophy (102)
Sponsored (13)
Startups (2122)
Stomach cancer (8)
Supply chain (38)
Tariffs (12)
The Weekly (8)
Vaccines (354)
Venture capitalists (13)
Weight loss (141)
Women's health (17)
Worklife (4)
Date
Today (82)
Last 7 days (403)
Last 30 days (1421)
Last 365 days (18478)
2025 (6005)
2024 (19857)
2023 (22756)
2022 (30701)
2021 (33009)
2020 (32207)
2019 (28435)
2018 (21830)
2017 (18929)
2016 (18125)
2015 (21216)
2014 (16033)
2013 (13252)
2012 (14357)
2011 (14634)
2010 (13191)
Location
Africa (354)
Alabama (18)
Alaska (2)
Arizona (118)
Arkansas (10)
Asia (24585)
Australia (3894)
California (3075)
Canada (1229)
China (374)
Colorado (165)
Connecticut (172)
Delaware (117)
Europe (48009)
Florida (546)
Georgia (126)
Idaho (33)
Illinois (360)
India (14)
Indiana (226)
Iowa (3)
Japan (121)
Kansas (73)
Kentucky (12)
Louisiana (7)
Maine (27)
Maryland (635)
Massachusetts (2145)
Michigan (109)
Minnesota (273)
Mississippi (2)
Missouri (52)
Montana (18)
Nebraska (18)
Nevada (33)
New Hampshire (60)
New Jersey (1135)
New Mexico (9)
New York (964)
North Carolina (555)
North Dakota (4)
Northern California (1341)
Ohio (131)
Oklahoma (3)
Oregon (23)
Pennsylvania (830)
Puerto Rico (7)
Rhode Island (24)
South America (520)
South Carolina (21)
Southern California (1186)
Tennessee (77)
Texas (543)
United States (12858)
Utah (112)
Virginia (80)
Washington D.C. (41)
Washington State (229)
West Virginia (3)
Wisconsin (42)
382,128 Results for "mainstay medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®
January 16, 2025
·
7 min read
Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients
Mainstay Medical Holdings plc announced the publication of a pooled analysis of three different clinical studies that evaluated the safety and efficacy of ReActiv8 therapy after two years in patients of various ages.
March 12, 2024
·
4 min read
FDA
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation System TM.
February 12, 2024
·
3 min read
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up
Mainstay Medical Holdings plc announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial.
March 19, 2024
·
4 min read
Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States
Mainstay Medical Holdings plc today announced the completion of enrollment in its RESTORE randomized clinical study of ReActiv8 for the treatment of intractable chronic low back pain.
August 29, 2023
·
6 min read
Press Releases
Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM
July 9, 2024
·
3 min read
Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom
Mainstay Medical Holdings plc today announced the publication of three-year clinical data from the Post-Market Clinical Follow-up (PMCF) study of 33 ReActiv8 patients from five medical centres across the United Kingdom.
July 20, 2023
·
4 min read
Policy
FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
QIAGEN announced that the U.S. Federal Bureau of Investigation has approved its ForenSeq® MainstAY workflow.
June 20, 2023
·
7 min read
Press Releases
Tenon Medical(R) Receives Approval for Notice of Allowance from the European Patent Office
March 11, 2025
·
2 min read
Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes data from its pivotal ReActiv8-B clinical trial.
September 28, 2022
·
5 min read
1 of 38,213
Next
